Editing Functional: Pharmacological Management of LUTS (section)

====== <span style="color:#ff0000">Adverse events[https://www.astellas.com/ca/system/files/pdf/Myrbetriq_PM_EN.pdf §]</span> ======
* '''<span style="color:#ff0000">≥1% (5)</span>'''
*# '''<span style="color:#ff0000">Hypertension</span>'''
*#* The mean increase (compared with placebo) in systolic and diastolic blood pressure after therapeutic doses of mirabegron once daily was ≈0.5-1 mm Hg and was reversible on discontinuation of treatment.
*#* In the clinical efficacy and safety studies, the change from baseline in mean pulse rate for mirabegron 50 mg was ≈1 beat/min and reversible on discontinuation of treatment.
*# '''<span style="color:#ff0000">Tachycardia</span>'''
*#'''<span style="color:#ff0000">Nasopharyngitis</span>'''
*#'''<span style="color:#ff0000">Urinary tract infection</span>'''
*#'''<span style="color:#ff0000">Headache</span>'''
*#'''<span style="color:#ff0000">Constipation</span>'''
*'''Does not cause increase QT interval'''
* '''Effects on HR and blood pressure need to be monitored when the drug is prescribed''', even if the cardiovascular effects of mirabegron observed in clinical studies have been minimal and clinically not relevant